Latest News for MBRX
Non-cardiotoxic anthracycline demonstrates activity where traditional chemotherapies have historically failed, supporting potential expansion of Annamycin into a major unmet-need indication
HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract highlighting data on its lead drug candidate, annamycin, has been accepted for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, Illinois.
HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced that an abstract highlighting data on its lead drug candidate, annamycin, has been accepted for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 - June 2, 2026, in Chicago, Illinois.
Access the Moleculin CEO Corner here
/PRNewswire/ -- USANewsGroup.com News Commentary - The global cell therapy manufacturing market is hitting a pivotal inflection point. It's projected to
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MBRX.
U.S. House Trading
No House trades found for MBRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.